| Time since switch to DOAC | Non‐persistent to all OAC (allowing a switch back to VKA) | Non‐persistent to DOAC (not allowing a switch back to VKA) | ||||||
|---|---|---|---|---|---|---|---|---|
| Follow‐up (years) | No. at risk | No. event | Cumulative incidence (95%CI) (%)* | Follow‐up (years) | No. at risk | No. event | Cumulative incidence (95%CI) (%)* | |
| TTR ≤ 45% | ||||||||
| 0‐6 months | 483.83 | 1132 | 43 | 4.12 (3.03‐5.45) | 466.82 | 1132 | 91 | 8.59 (7‐10.38) |
| 0‐1 year | 857.31 | 1132 | 80 | 8.52 (6.83‐10.43) | 819.23 | 1132 | 133 | 13.58 (11.49‐15.83) |
| 0‐4 year | 1697.32 | 1132 | 141 | 24.06 (19.63‐28.75) | 1584.05 | 1132 | 195 | 29.69 (24.91‐34.62) |
| TTR > 45% | ||||||||
| 0‐6 months | 1335.69 | 2968 | 81 | 2.87 (2.3‐3.54) | 1291.54 | 2968 | 195 | 6.83 (5.94‐7.8) |
| 0‐1 year | 2434.01 | 2968 | 124 | 4.69 (3.92‐5.54) | 2332.42 | 2968 | 256 | 9.42 (8.35‐10.56) |
| 0‐4 year | 5518.46 | 2968 | 267 | 16.16 (14.13‐18.31) | 5185.26 | 2968 | 389 | 20.26 (18.15‐22.45) |
*estimated by cumulative incidence competing risk (CICR) method.
Abbreviations: OAC, oral anticoagulants; DOAC, direct oral anticoagulants; VKA, Vitamin K antagonists; CI, confidence interval; TTR, time in therapeutic range.